Aller au contenu

Épisode 28 : Étude DAPA-HF

Efficacité de la dapagliflozine chez les sujets avec insuffisance cardiaque à fraction d’éjection diminuée (étude DAPA-HF)

Diffusé le 17 octobre 2019

Dans cette 28e baladodiffusion, les Drs Luc Lanthier et et Charles Dussault discutent de l’efficacité de la dapagliflozine (Forxiga®), un inhibiteur des SGLT2, chez les sujets avec insuffisance cardiaque à fraction d’éjection diminuée avec l’étude DAPA-HF, en plus de réviser la littérature médicale de septembre 2019.

Quiz clinique (3 min 15), article principal (3 min 45), critique (21 min 40), autres articles (32 min 27), réponse au quiz clinique (45 min 00)

Référence principale

McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. PubMed PMID: 31535829.

Infographie

Article résumé

Lanthier L, Dussault C, Huard G, Plourde MÉ, Cauchon M. Chez les sujets avec insuffisance cardiaque à fraction d’éjection diminuée avec ou sans diabète de type 2, est-ce que la dapagliflozine, un inhibiteur des SGLT2, est efficace pour prévenir l’insuffisance cardiaque décompensée ou la mortalité cardiovasculaire tout en étant sécuritaire ? Rev Med Interne. 2020;41(2):143-144. PubMed PMID: 31928796

Articles associés

https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-51. PubMed PMID: 31185157.

Nassif ME, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019;140(18):1463-76. PubMed PMID: 31524498.

Fang JC. Heart-Failure Therapy - New Drugs but Old Habits? N Engl J Med. 2019;381(21):2063-64. PubMed PMID: 31535828.

Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019;381(16):1524-34. PubMed PMID: 31475799.

Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-43. PubMed PMID: 31492505.

Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381(21): 2032-42. PubMed PMID: 31556978.

Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, et al. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med. 2019;381(19):1820-30. PubMed PMID: 31562798.

Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351-66. PubMed PMID: 30025570.

Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;73(19):2365-83. PubMed PMID: 30844480.

Autres articles d'intérêt récents

Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-13. PubMed PMID: 31475793.

Mrkobrada M, Chan MTV, Cowan D, Campbell D, Wang CY, Torres D, et al. Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. Lancet. 2019;394(10203):1022-9. PubMed PMID: 31422895.

Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919-28. PubMed PMID: 31451207.

Guides de pratique récents

GINA asthme : https://ginasthma.org/gina-reports/

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-12. PubMed PMID: 31385462.

Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, et al. Canadian guideline for Parkinson disease. CMAJ. 2019;191(36):E989-E1004. PubMed PMID: 31501181.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e563-e95PubMed PMID: 30879339.